Related Experiment Video
Updated: Aug 11, 2025
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomized Clinical Trial (MAGiCAL-CKD)
Iain Bressendorff1,2, Ditte Hansen2, Morten Schou3
1Department of Endocrinology and Nephrology, Nordsjællands Hospital, Hillerød, Denmark.
Insights
Magnesium supplementation did not prevent vascular calcification in patients with chronic kidney disease (CKD). This study found no benefit and a higher risk of adverse events with magnesium in CKD patients.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Lower serum magnesium is linked to increased cardiovascular risk in chronic kidney disease (CKD).
- Magnesium has shown promise in preventing vascular calcification in animal models of CKD.
Purpose of the Study:
- To evaluate the efficacy of oral magnesium supplementation in slowing vascular calcification progression in predialysis CKD patients.
- To assess the safety profile of magnesium supplementation in this patient population.
Main Methods:
- A 12-month randomized, double-blind, placebo-controlled trial involving 148 predialysis CKD patients (eGFR 15-45 ml/min).
- Participants received either oral magnesium hydroxide (15 mmol twice daily) or a placebo.
- The primary endpoint was the change in coronary artery calcification (CAC) score over 12 months.
Main Results:
- Despite significant increases in plasma magnesium, no significant difference in CAC score progression was observed between the magnesium and placebo groups.
- The magnesium group experienced a higher incidence of gastrointestinal adverse events, serious adverse events, deaths, and cardiovascular events compared to placebo.
Conclusions:
- Oral magnesium supplementation for 12 months did not slow vascular calcification progression in CKD patients.
- Magnesium supplementation alone may not be sufficient for cardiovascular risk reduction in CKD, necessitating alternative therapeutic strategies.
Significance Statement:
Magnesium prevents vascular calcification in animals with CKD. In addition, lower serum magnesium is associated with higher risk of cardiovascular events in CKD. In a randomized, double-blinded, placebo-controlled trial, the authors investigated the effects of magnesium supplementation versus placebo on vascular calcification in patients with predialysis CKD. Despite significant increases in plasma magnesium among study participants who received magnesium compared with those who received placebo, magnesium supplementation did not slow the progression of vascular calcification in study participants. In addition, the findings showed a higher incidence of serious adverse events in the group treated with magnesium. Magnesium supplementation alone was not sufficient to delay progression of vascular calcification, and other therapeutic strategies might be necessary to reduce the risk of cardiovascular disease in CKD.
Background:
Elevated levels of serum magnesium are associated with lower risk of cardiovascular events in patients with CKD. Magnesium also prevents vascular calcification in animal models of CKD.
Methods:
To investigate whether oral magnesium supplementation would slow the progression of vascular calcification in CKD, we conducted a randomized, double-blinded, placebo-controlled, parallel-group, clinical trial. We enrolled 148 subjects with an eGFR between 15 and 45 ml/min and randomly assigned them to receive oral magnesium hydroxide 15 mmol twice daily or matching placebo for 12 months. The primary end point was the between-groups difference in coronary artery calcification (CAC) score after 12 months adjusted for baseline CAC score, age, and diabetes mellitus.
Results:
A total of 75 subjects received magnesium and 73 received placebo. Median eGFR was 25 ml/min at baseline, and median baseline CAC scores were 413 and 274 in the magnesium and placebo groups, respectively. Despite plasma magnesium increasing significantly during the trial in the magnesium group, the baseline-adjusted CAC scores did not differ significantly between the two groups after 12 months. Prespecified subgroup analyses according to CAC>0 at baseline, diabetes mellitus, or tertiles of serum calcification propensity did not significantly alter the main results. Among subjects who experienced gastrointestinal adverse effects, 35 were in the group receiving magnesium treatment versus nine in the placebo group. Five deaths and six cardiovascular events occurred in the magnesium group compared with two deaths and no cardiovascular events in the placebo group.
Conclusions:
Magnesium supplementation for 12 months did not slow the progression of vascular calcification in CKD, despite a significant increase in plasma magnesium.
Clinical Trials Registration:
www.clinicaltrials.gov ( NCT02542319 ).
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations
01:20Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:25Chronic Kidney Disease I: Introduction
01:18Chronic Kidney Disease IV: Nursing Management